HN
Hansa Biopharma AB
HNSBF · OTC
$3.70 +0.00% (+$0.00)
Market Cap 3.63B kr
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 19.19x
P/E N/A
EV/EBITDA N/A
Growth
79 /100
Growing Rev. growth 12.88%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 57.34%
Net margin 406.19%
Op. margin 310.69%
Quality
3 /100
Poor ROIC 71.73%
ROA 71.74%
Asset turnover 0.18x
Debt
23 /100
High Current ratio 1.25x
Int. coverage -3.06x
Debt/Equity N/A
Stability
39 /100
Moderate Beta 1.58x
Rev. volatility 24.25%
EPS volatility 32.73%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o HNSBF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Renée Julie Elisabet Aguiar-Lucander
Employees
125
Headquarters
Lund
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report